These promising preclinical findings in translationally relevant models suggest that linagliptin may prevent the onset of DD in insulin resistant states caused by overnutrition, as well as improve DD in the setting of established insulin resistance, obesity and T2DM when there is a pre-existing cardiac relaxation abnormality. Here, INS is linked to type 2 diabetes mellitus.